Ontology highlight
ABSTRACT:
SUBMITTER: Looyenga BD
PROVIDER: S-EPMC3069649 | biostudies-literature | 2011 Apr
REPOSITORIES: biostudies-literature
Looyenga Brendan D BD Cherni Irene I Mackeigan Jeffrey P JP Weiss Glen J GJ
Translational oncology 20110401 2
Tyrosine kinase inhibitors (TKIs) have been in use as cancer therapeutics for nearly a decade, and their utility in targeting specific malignancies with defined genetic lesions has proven to be remarkably effective. Recent efforts to characterize the spectrum of genetic lesions found in non-small cell lung carcinoma (NSCLC) have provided important insights into the molecular basis of this disease and have also revealed a wide array of tyrosine kinases that might be effectively targeted for ratio ...[more]